Don Beck Ledyard
Publication: The Day
The juxtaposition of Lee Howard's articles in The Day, "Pfizer CEO gets 12.5% raise from last year's $14.9M," published March 4, and "Pfizer Alzheimer's drug proves ineffective," published Feb. 26, were telling.
Pfizer Chief Executive Officer Jeff Kindler's raise was supported by the "increased complexity of the organization," and Mr. Kindler's role in the $67 billion Wyeth deal (that the Pfizer shareholders continue to finance.)
In the Alzheimer's article, Dimebon - is that pronounced "time bomb?" was described as a failure for Pfizer.
Couple these events with the performance of Pfizer stock: a dividend payout of $1.28 per share in 2008; $0.80 per share in 2009 (after a draconian reduction in the dividend for three quarters) and now in 2010 a change in the dividend to $0.72 per share that will result in a decreased yearly dividend. Is this change you can believe in?
In the meantime, the smaller, less-complex competitors move along with dividends well above $1 per share. Welcome to "Alice in Wonderland."
With the Valentine's Day holiday approaching, we wanted to see if any of our readers ever received a Valentine's gift that was memorably bad.
With the Valentine's Day holiday approaching, we wanted to see if any of our readers ever received a Valentine's gift that was memorably bad.
In the past two weeks our Facebook fans have won tickets to the CT Tigers, Newport Winefest and Mystic Seaport. Become a fan of The Day on Facebook for access to these contests, breaking news, TheDay.com's best features and more!
HIDE COMMENTS
Why did Pfizer CEO deserve a raise?
The juxtaposition of Lee Howard's articles in The Day, "Pfizer CEO gets 12.5% raise from last year's $14.9M," published March 4, and "Pfizer Alzheimer's drug proves ineffective," published Feb. 26,...
HIDE COMMENTS